Zhang Yuanyuan, Chen Lisha, Chen Huixin
Department of Gastroenterology, Huizhou Municipal Center Hospital Huizhou 516001, Guangdong Province, China.
Am J Transl Res. 2021 Apr 15;13(4):2432-2438. eCollection 2021.
The purpose of this study was to evaluate the effect of non-steroidal anti-inflammatory drugs (NSAIDs) on the recurrence risk of colorectal adenomas through a meta-analysis of published studies.
A meta-analysis was performed to evaluate the effect of NSAIDs on the incidence rates of colorectal adenomatous polyps, using PubMed, Ovid, Elsevier, and other journal databases. Data were processed using Review Manager 5.3 and random errors were calculated using trial sequential analysis (TSA).
A total of 8 studies published between 2003 and 2014 were selected. In the data collected, the patients on long-term usage of low-dose NSAIDs were shown to have significantly lower risk of colorectal adenoma compared with those on placebos (RR=0.80, 95% CI=0.70-0.92), with relatively low random errors. Long-term usage of low-dose NSAIDs was also found to have inhibitory effects on advanced adenomas (RR=0.66, 95% CI=0.44-0.99), but with relatively high random errors. Besides, high-dose NSAIDs were also shown to have inhibitory but inconsistent effects on adenomas and advanced adenomas (RR=0.66, 95% CI=0.59-0.72), and the withdrawal was associated with increased risks of the disease.
These results suggest that low-dose NSAIDs have an inhibitory effect on recurrent adenomas, but the efficacy for late-stage adenomas remain inconclusive. The withdrawal of the drug might be associated with increased risks of the disease.
本研究旨在通过对已发表研究的荟萃分析,评估非甾体抗炎药(NSAIDs)对结直肠腺瘤复发风险的影响。
利用PubMed、Ovid、爱思唯尔等期刊数据库进行荟萃分析,以评估NSAIDs对结直肠腺瘤性息肉发病率的影响。使用Review Manager 5.3处理数据,并通过试验序贯分析(TSA)计算随机误差。
共选取了2003年至2014年间发表的8项研究。在所收集的数据中,长期使用低剂量NSAIDs的患者与使用安慰剂的患者相比,结直肠腺瘤风险显著降低(RR=0.80,95%CI=0.70-0.92),随机误差相对较低。还发现长期使用低剂量NSAIDs对晚期腺瘤有抑制作用(RR=0.66,95%CI=0.44-0.99),但随机误差相对较高。此外,高剂量NSAIDs对腺瘤和晚期腺瘤也有抑制作用,但效果不一致(RR=0.66,95%CI=0.59-0.72),且停药与疾病风险增加有关。
这些结果表明,低剂量NSAIDs对复发性腺瘤有抑制作用,但对晚期腺瘤的疗效仍不确定。停药可能与疾病风险增加有关。